213 related articles for article (PubMed ID: 31372342)
1. Future clinical and biochemical predictions of Fabry disease in females by methylation studies of the
Hossain MA; Wu C; Yanagisawa H; Miyajima T; Akiyama K; Eto Y
Mol Genet Metab Rep; 2019 Sep; 20():100497. PubMed ID: 31372342
[TBL] [Abstract][Full Text] [Related]
2. The severe clinical phenotype for a heterozygous Fabry female patient correlates to the methylation of non-mutated allele associated with chromosome 10q26 deletion syndrome.
Hossain MA; Yanagisawa H; Miyajima T; Wu C; Takamura A; Akiyama K; Itagaki R; Eto K; Iwamoto T; Yokoi T; Kurosawa K; Numabe H; Eto Y
Mol Genet Metab; 2017 Mar; 120(3):173-179. PubMed ID: 28087245
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive testing algorithm for the diagnosis of Fabry disease in males and females.
Stiles AR; Zhang H; Dai J; McCaw P; Beasley J; Rehder C; Koeberl DD; McDonald M; Bali DS; Young SP
Mol Genet Metab; 2020 Jul; 130(3):209-214. PubMed ID: 32418857
[TBL] [Abstract][Full Text] [Related]
4. Plasma mutant α-galactosidase A protein and globotriaosylsphingosine level in Fabry disease.
Tsukimura T; Nakano S; Togawa T; Tanaka T; Saito S; Ohno K; Shibasaki F; Sakuraba H
Mol Genet Metab Rep; 2014; 1():288-298. PubMed ID: 27896103
[TBL] [Abstract][Full Text] [Related]
5. X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay.
Rossanti R; Nozu K; Fukunaga A; Nagano C; Horinouchi T; Yamamura T; Sakakibara N; Minamikawa S; Ishiko S; Aoto Y; Okada E; Ninchoji T; Kato N; Maruyama S; Kono K; Nishi S; Iijima K; Fujii H
Clin Exp Nephrol; 2021 Nov; 25(11):1224-1230. PubMed ID: 34128148
[TBL] [Abstract][Full Text] [Related]
6. Plasma globotriaosylsphingosine as a biomarker of Fabry disease.
Togawa T; Kodama T; Suzuki T; Sugawara K; Tsukimura T; Ohashi T; Ishige N; Suzuki K; Kitagawa T; Sakuraba H
Mol Genet Metab; 2010 Jul; 100(3):257-61. PubMed ID: 20409739
[TBL] [Abstract][Full Text] [Related]
7. Does administration of hydroxychloroquine/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?
Tsukimura T; Shiga T; Saito K; Ogawa Y; Sakuraba H; Togawa T
Mol Genet Metab Rep; 2021 Sep; 28():100773. PubMed ID: 34136356
[TBL] [Abstract][Full Text] [Related]
8. DNA methylation impact on Fabry disease.
Di Risi T; Vinciguerra R; Cuomo M; Della Monica R; Riccio E; Cocozza S; Imbriaco M; Duro G; Pisani A; Chiariotti L
Clin Epigenetics; 2021 Feb; 13(1):24. PubMed ID: 33531072
[TBL] [Abstract][Full Text] [Related]
9. AAV2/6 Gene Therapy in a Murine Model of Fabry Disease Results in Supraphysiological Enzyme Activity and Effective Substrate Reduction.
Yasuda M; Huston MW; Pagant S; Gan L; St Martin S; Sproul S; Richards D; Ballaron S; Hettini K; Ledeboer A; Falese L; Cao L; Lu Y; Holmes MC; Meyer K; Desnick RJ; Wechsler T
Mol Ther Methods Clin Dev; 2020 Sep; 18():607-619. PubMed ID: 32775495
[TBL] [Abstract][Full Text] [Related]
10. X-chromosomal inactivation patterns in women with Fabry disease.
Wagenhäuser L; Rickert V; Sommer C; Wanner C; Nordbeck P; Rost S; Üçeyler N
Mol Genet Genomic Med; 2022 Sep; 10(9):e2029. PubMed ID: 35971858
[TBL] [Abstract][Full Text] [Related]
11. High-Risk Screening of Fabry Disease: Analysis of Fifteen Urinary Methylated and Non-Methylated Gb
Abaoui M; Boutin M; Lavoie P; Auray-Blais C
Curr Protoc Hum Genet; 2016 Oct; 91():17.24.1-17.24.11. PubMed ID: 27727434
[TBL] [Abstract][Full Text] [Related]
12. Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy.
Tsukimura T; Tayama Y; Shiga T; Hirai K; Togawa T; Sakuraba H
Mol Genet Metab Rep; 2020 Dec; 25():100650. PubMed ID: 33072516
[TBL] [Abstract][Full Text] [Related]
13. Distinctive accumulation of globotriaosylceramide and globotriaosylsphingosine in a mouse model of classic Fabry disease.
Taguchi A; Ishii S; Mikame M; Maruyama H
Mol Genet Metab Rep; 2023 Mar; 34():100952. PubMed ID: 36624895
[TBL] [Abstract][Full Text] [Related]
14. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
15. Tissue and plasma globotriaosylsphingosine could be a biomarker for assessing enzyme replacement therapy for Fabry disease.
Togawa T; Kawashima I; Kodama T; Tsukimura T; Suzuki T; Fukushige T; Kanekura T; Sakuraba H
Biochem Biophys Res Commun; 2010 Sep; 399(4):716-20. PubMed ID: 20692233
[TBL] [Abstract][Full Text] [Related]
16. Elevated Lyso-Gb3 Suggests the R118C GLA Mutation Is a Pathological Fabry Variant.
Talbot A; Nicholls K
JIMD Rep; 2019; 45():95-98. PubMed ID: 30569317
[TBL] [Abstract][Full Text] [Related]
17. Correlation of Lyso-Gb3 levels in dried blood spots and sera from patients with classic and Later-Onset Fabry disease.
Nowak A; Mechtler T; Kasper DC; Desnick RJ
Mol Genet Metab; 2017 Aug; 121(4):320-324. PubMed ID: 28663131
[TBL] [Abstract][Full Text] [Related]
18. Multiplex tandem mass spectrometry analysis of novel plasma lyso-Gb₃-related analogues in Fabry disease.
Boutin M; Auray-Blais C
Anal Chem; 2014 Apr; 86(7):3476-83. PubMed ID: 24634980
[TBL] [Abstract][Full Text] [Related]
19. LC-MS lipidomics of renal biopsies for the diagnosis of Fabry disease.
Yazd HS; Bazargani SF; Vanbeek CA; King-Morris K; Heldermon C; Segal MS; Clapp WL; Garrett TJ
J Mass Spectrom Adv Clin Lab; 2021 Nov; 22():71-78. PubMed ID: 34918004
[TBL] [Abstract][Full Text] [Related]
20. Female Fabry disease patients and X-chromosome inactivation.
Juchniewicz P; Kloska A; Tylki-Szymańska A; Jakóbkiewicz-Banecka J; Węgrzyn G; Moskot M; Gabig-Cimińska M; Piotrowska E
Gene; 2018 Jan; 641():259-264. PubMed ID: 29079200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
